Expression and clinical significance of SERPINA3 and EFEMP2 in endometrial carcinoma

Our study aimed to investigate expression and clinical significance of serpin peptidase inhibitor clade A member 3 (SERPINA3) and epidermal growth factor (EGF) containing fibulin-like extracellular matrix protein 2 (EFEMP2) in endometrial carcinoma. A total of 180 patients treated in our hospital fr...

Full description

Bibliographic Details
Main Authors: Shaoguang Wang, Yaozong Dong, Xiaomei Meng
Format: Article
Language:English
Published: SAGE Publishing 2018-06-01
Series:European Journal of Inflammation
Online Access:https://doi.org/10.1177/2058739218781125
id doaj-d368350bddce4f1d8110f4c7819f7c12
record_format Article
spelling doaj-d368350bddce4f1d8110f4c7819f7c122020-11-25T03:26:30ZengSAGE PublishingEuropean Journal of Inflammation2058-73922018-06-011610.1177/2058739218781125Expression and clinical significance of SERPINA3 and EFEMP2 in endometrial carcinomaShaoguang WangYaozong DongXiaomei MengOur study aimed to investigate expression and clinical significance of serpin peptidase inhibitor clade A member 3 (SERPINA3) and epidermal growth factor (EGF) containing fibulin-like extracellular matrix protein 2 (EFEMP2) in endometrial carcinoma. A total of 180 patients treated in our hospital from January 2015 to April 2017 were selected as subjects. Positive expression of SERPINA3 was found in 48 cases (80%) in the cancer group, in 6 cases (10%) in the hyperplasia group, and in no case in the control group. The expression of SERPINA3 in the cancer group was significantly higher than that in the hyperplasia group and control group ( P  < 0.05). Positive expression of EFEMP2 was found in 10 cases (16.7%) in the cancer group, in 27 cases (45%) in the hyperplasia group, and in 42 cases (70%) in the control group. The expression of EFEMP2 in the cancer group was significantly lower than that in the hyperplasia and control groups ( P  < 0.05). The protein expression of SERPINA3 in the cancer group was significantly higher than that in the hyperplasia and control groups ( P  < 0.05). The protein expression of EFEMP2 in the cancer group was significantly lower than that in the hyperplasia and control groups ( P  < 0.05). The expression of SERPINA3 and EFEMP2 in cancer tissues was related to the degree of tumor differentiation, clinical classification, and lymph node metastasis ( P  < 0.05), but not related to age and tumor size ( P  > 0.05). SERPINA3 was highly expressed while EFEMP2 was low expressed in endometrial cancer patients. The expression of SERPINA3 and EFEMP2 in cancer tissues was related to the degree of tumor differentiation, clinical classification, and lymph node metastasis and was hopeful to be one of the detection indexes of endometrial carcinoma.https://doi.org/10.1177/2058739218781125
collection DOAJ
language English
format Article
sources DOAJ
author Shaoguang Wang
Yaozong Dong
Xiaomei Meng
spellingShingle Shaoguang Wang
Yaozong Dong
Xiaomei Meng
Expression and clinical significance of SERPINA3 and EFEMP2 in endometrial carcinoma
European Journal of Inflammation
author_facet Shaoguang Wang
Yaozong Dong
Xiaomei Meng
author_sort Shaoguang Wang
title Expression and clinical significance of SERPINA3 and EFEMP2 in endometrial carcinoma
title_short Expression and clinical significance of SERPINA3 and EFEMP2 in endometrial carcinoma
title_full Expression and clinical significance of SERPINA3 and EFEMP2 in endometrial carcinoma
title_fullStr Expression and clinical significance of SERPINA3 and EFEMP2 in endometrial carcinoma
title_full_unstemmed Expression and clinical significance of SERPINA3 and EFEMP2 in endometrial carcinoma
title_sort expression and clinical significance of serpina3 and efemp2 in endometrial carcinoma
publisher SAGE Publishing
series European Journal of Inflammation
issn 2058-7392
publishDate 2018-06-01
description Our study aimed to investigate expression and clinical significance of serpin peptidase inhibitor clade A member 3 (SERPINA3) and epidermal growth factor (EGF) containing fibulin-like extracellular matrix protein 2 (EFEMP2) in endometrial carcinoma. A total of 180 patients treated in our hospital from January 2015 to April 2017 were selected as subjects. Positive expression of SERPINA3 was found in 48 cases (80%) in the cancer group, in 6 cases (10%) in the hyperplasia group, and in no case in the control group. The expression of SERPINA3 in the cancer group was significantly higher than that in the hyperplasia group and control group ( P  < 0.05). Positive expression of EFEMP2 was found in 10 cases (16.7%) in the cancer group, in 27 cases (45%) in the hyperplasia group, and in 42 cases (70%) in the control group. The expression of EFEMP2 in the cancer group was significantly lower than that in the hyperplasia and control groups ( P  < 0.05). The protein expression of SERPINA3 in the cancer group was significantly higher than that in the hyperplasia and control groups ( P  < 0.05). The protein expression of EFEMP2 in the cancer group was significantly lower than that in the hyperplasia and control groups ( P  < 0.05). The expression of SERPINA3 and EFEMP2 in cancer tissues was related to the degree of tumor differentiation, clinical classification, and lymph node metastasis ( P  < 0.05), but not related to age and tumor size ( P  > 0.05). SERPINA3 was highly expressed while EFEMP2 was low expressed in endometrial cancer patients. The expression of SERPINA3 and EFEMP2 in cancer tissues was related to the degree of tumor differentiation, clinical classification, and lymph node metastasis and was hopeful to be one of the detection indexes of endometrial carcinoma.
url https://doi.org/10.1177/2058739218781125
work_keys_str_mv AT shaoguangwang expressionandclinicalsignificanceofserpina3andefemp2inendometrialcarcinoma
AT yaozongdong expressionandclinicalsignificanceofserpina3andefemp2inendometrialcarcinoma
AT xiaomeimeng expressionandclinicalsignificanceofserpina3andefemp2inendometrialcarcinoma
_version_ 1724592364873318400